HomeFOLD • NASDAQ
Amicus Therapeutics, Inc.
add
Financials
Income Statement
Revenue
Net Income
Revenue
Net income
| (USD) | Mar 2025info | Y/Y change |
|---|---|---|
Revenue | 125.25M | 13.45% |
Operating expense | 121.50M | 2.52% |
Net income | -21.69M | 55.21% |
Net profit margin | -17.31 | 60.53% |
Earnings per share | 0.03 | 250.00% |
EBITDA | -6.12M | 68.68% |
Effective tax rate | -20.18% | — |
Balance Sheet
Total Assets
Total Liabilities
Total assets
Total liabilities
| (USD) | Mar 2025info | Y/Y change |
|---|---|---|
Cash and short-term investments | 250.57M | 4.58% |
Total assets | 789.84M | 9.43% |
Total liabilities | 596.28M | 0.88% |
Total equity | 193.56M | — |
Shares outstanding | 307.93M | — |
Price to book | 9.44 | — |
Return on assets | -2.52% | — |
Return on capital | -3.12% | — |
Cash Flow
Net Change in Cash
Net change in cash
| (USD) | Mar 2025info | Y/Y change |
|---|---|---|
Net income | -21.69M | 55.21% |
Cash from operations | 7.76M | 126.13% |
Cash from investing | -32.86M | -536.00% |
Cash from financing | -11.70M | 12.09% |
Net change in cash | -31.98M | 14.21% |
Free cash flow | 13.92M | 239.87% |
Previous close
$5.95
Day range
$5.91 - $6.02
Year range
$5.81 - $12.65
Market cap
1.83B USD
Avg Volume
4.96M
P/E ratio
-
Dividend yield
-
Primary exchange
NASDAQ
About
Amicus Therapeutics, Inc. is a public American biopharmaceutical company based in Philadelphia, PA. The company went public in 2007 under the NASDAQ trading symbol FOLD. This followed a 2006 planned offering and subsequent withdrawal, which would have established the trading symbol as AMTX Prior to their IPO, Amicus was funded by a variety of venture capital firms including Radius Ventures, Canaan Partners and New Enterprise Associates. Wikipedia
Founded
Feb 4, 2002
Website
Employees
499
